Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
A loss of -2.140% shows a downward development for Pacira Pharmaceuticals.
Pacira Pharmaceuticals is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 47 € shows a very positive potential of 71.53% compared to the current price of 27.4 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -2.140% | 15.702% | 15.702% | -25.926% | -6.040% | -44.000% | -30.157% |
| Rockwell Medical Inc. | -1.140% | 7.400% | 11.881% | -25.553% | -8.766% | -80.708% | -96.719% |
| Avid Bioservices Inc | 1.820% | 4.430% | 28.906% | -47.115% | 35.246% | -49.387% | 158.702% |
| Gritstone Oncology Inc | -0.920% | -24.973% | -0.650% | -63.751% | -62.971% | -89.890% | - |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $45.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat